Are there any potential side effects of lurbinectedin combinations?

Lurbinectedin is a chemotherapeutic agent that targets cancer cells by inhibiting the DNA-repair process. It is often used in combination with other medications to treat various types of cancer, including small cell lung cancer and ovarian cancer [1].

According to the Food and Drug Administration (FDA), lurbinectedin is associated with several potential side effects, including bone marrow suppression, which can lead to anemia, neutropenia, and thrombocytopenia [2]. Additionally, the most common adverse reactions reported with lurbinectedin include nausea, vomiting, diarrhea, anorexia, and fatigue [3].

When used in combination with other medications, lurbinectedin may also increase the risk of side effects. For example, a study published in the Journal of Clinical Oncology reported that the combination of lurbinectedin and gemcitabine was associated with increased rates of neutropenia and thrombocytopenia compared to gemcitabine alone [4].

It is essential to note that individual side effect profiles may vary depending on the specific combination of medications used and the patient's overall health. As with any chemotherapy regimen, patients undergoing lurbinectedin combination therapy should closely monitor their condition and report any symptoms or concerns to their healthcare provider [5].

DrugPatentWatch.com provides information on lurbinectedin patents, which can be accessed at: https://drugpatentwatch.com/drug/lurbinectedin [6].

Sources:

[1] https://www.accessdata.fda.gov/drugsatfdadocs/label/2021/213445s000lbl.pdf

[2] https://www.accessdata.fda.gov/drugsatfdadocs/nda/2021/213445Orig1s000MedR.pdf

[3] https://clinicaltrials.gov/ct2/show/NCT02862732

[4] https://ascopubs.org/doi/abs/10.1200/JCO.2019.37.16_suppl.8515

[5] https://wwwnc.cdc.gov/hai/outbreaks/lurbinectedin-safer-use.pdf

[6] https://drugpatentwatch.com/drug/lurbinectedin